Exicure, Inc. to Present at the 2020 BMO Prescription for Success Healthcare Conference

Exicure, Inc. XCUR, the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present a corporate update at the virtual 2020 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 4:30 p.m. EDT.

A live audio webcast will be available on the Investors section of Exicure's website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN, an SNA–based therapeutic candidate for the treatment of Friedreich's ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and also has an office in Cambridge, MA. For more information, visit Exicure's website at www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005073/en/